These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24852729)

  • 1. Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.
    Timur AA; Murugesan G; Zhang L; Barnard J; Bhatt DL; Kottke-Marchant K
    Thromb Res; 2014 Jul; 134(1):96-104. PubMed ID: 24852729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
    Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
    Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.
    Good RI; McGarrity A; James TE; Miller H; McConnachie A; Goodall AH; Oldroyd KG
    Thromb Res; 2015 Jun; 135(6):1140-6. PubMed ID: 25746368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients.
    Paniccia R; Antonucci E; Gori AM; Marcucci R; Giglioli C; Antoniucci D; Gensini GF; Abbate R; Prisco D
    J Thromb Haemost; 2007 Sep; 5(9):1839-47. PubMed ID: 17723123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.
    Liang Y; Johnston M; Hirsh J; Pare G; Li C; Mehta S; Teo KK; Sloane D; Yi Q; Zhu J; Eikelboom JW
    J Thromb Thrombolysis; 2012 Nov; 34(4):429-36. PubMed ID: 22797934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
    Bouman HJ; Parlak E; van Werkum JW; Breet NJ; ten Cate H; Hackeng CM; ten Berg JM; Taubert D
    J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease.
    Liu T; Zhang J; Chen X; Feng X; Fu SW; McCaffrey TA; Liu M
    Gene; 2015 Oct; 571(1):23-7. PubMed ID: 26095809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function tests.
    Golański J; Syska K; Chiżynski K; Kassasir H; Watała C; Sakowicz A; Kuliczkowski W
    Pol Arch Med Wewn; 2016 Aug; 126(9):653-661. PubMed ID: 27534914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
    Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
    Am J Cardiol; 2009 Nov; 104(9):1189-93. PubMed ID: 19840560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
    Kim IS; Jeong YH; Tantry US; Park Y; Lee DH; Bliden KP; Koh JS; Park JR; Jang JS; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S; Gurbel PA
    Am Heart J; 2013 Jul; 166(1):95-103. PubMed ID: 23816027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.
    Yao Y; Zhang JH; Tang XF; He C; Ma YL; Xu JJ; Song Y; Liu R; Meng XM; Song L; Wang M; Gao RL; Yuan JQ
    Chin Med J (Engl); 2016 Oct; 129(19):2269-74. PubMed ID: 27647183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
    Wagner H; Angiolillo DJ; Ten Berg JM; Bergmeijer TO; Jakubowski JA; Small DS; Moser BA; Zhou C; Brown P; James S; Winters KJ; Erlinge D
    J Thromb Thrombolysis; 2014; 38(2):127-36. PubMed ID: 24043374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia.
    Clavijo LC; Al-Asady N; Dhillon A; Matthews RV; Caro J; Tun H; Rowe V; Shavelle DM
    Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):516-520. PubMed ID: 29221961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.
    Zhang HZ; Kim MH; Han JY; Jeong YH
    Platelets; 2014; 25(4):285-91. PubMed ID: 23971745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy.
    Choi PA; Parry PV; Bauer JS; Zusman BE; Panczykowski DM; Puccio AM; Okonkwo DO
    Neurosurgery; 2017 Jan; 80(1):98-104. PubMed ID: 28362883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.